KALA BIO, Inc. — Director's Dealing 2020

Apr 1, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kala Pharmaceuticals, Inc. (KALA)
CIK: 0001479419
Period of Report: 2020-03-30

Reporting Person: Chen Hongming (Chief Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-03-30	Common Stock	M	31000	$2.30	Acquired	86849	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-03-30	Stock Option (right to buy)	$2.30	M	31000	Disposed	2024-10-01	Common Stock (31000)	Direct

Footnotes

F1: The option became fully vested on July 21, 2018.